Atherosclerosis
Volume 213, Issue 1 , Pages 67-76 , November 2010

Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway

  • Matthew J. Lovell

      Affiliations

    • Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • These authors have contributed equally and are joint first authors of this article.
    • ,
  • Mohammed Yasin

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • These authors have contributed equally and are joint first authors of this article.
    • ,
  • Kate L. Lee

      Affiliations

    • Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • King Kenneth Cheung

      Affiliations

    • Centre for Advanced Biomedical Imaging, Department of Medicine and Institute of Child Health, University College London, London WC1E 6DD, UK
    • Department of Medical Physics and Bioengineering, University College London, London WC1E 6DD, UK
    • ,
  • Yasunori Shintani

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Massimo Collino

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Ahila Sivarajah

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Kit-yi Leung

      Affiliations

    • Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Kunihiko Takahashi

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Amar Kapoor

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Mohammed M. Yaqoob

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Ken Suzuki

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Mark F. Lythgoe

      Affiliations

    • Centre for Advanced Biomedical Imaging, Department of Medicine and Institute of Child Health, University College London, London WC1E 6DD, UK
    • ,
  • John Martin

      Affiliations

    • British Heart Foundation Laboratories, Department of Medicine, University College London, London WC1E 6JJ, UK
    • ,
  • Patricia B. Munroe

      Affiliations

    • Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • ,
  • Chris Thiemermann

      Affiliations

    • Centre for Translational Medicine & Therapeutics, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • These authors have contributed equally and are joint last authors of this article.
    • ,
  • Anthony Mathur

      Affiliations

    • Centre for Clinical Pharmacology, Cardiovascular Biomedical Research Unit, The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    • These authors have contributed equally and are joint last authors of this article.
    • Corresponding Author InformationCorresponding author. Tel.: +44 208 983 2216; fax: +44 208 983 2381.

Received 13 January 2010 ,Revised 22 July 2010 ,Accepted 23 July 2010.

References 

  1. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7(4):430–436
  2. Rota M, Kajstura J, Hosoda T, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci USA. 2007;104(45):17783–17788
  3. Balsam LB, Wagers AJ, Christensen JL, et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428(6983):668–673
  4. Xu M, Uemura R, Dai Y, et al. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol. 2007;42(2):441–448
  5. Burchfield JS, Iwasaki M, Koyanagi M, et al. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res. 2008;103(2):203–211
  6. Rota M, Padin-Iruegas ME, Misao Y, et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res. 2008;103(1):107–116
  7. Dimmeler S, Zeiher AM. Cell therapy of acute myocardial infarction: open questions. Cardiology. 2009;113(3):155–160
  8. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348(9030):771–775
  9. Iihoshi S, Honmou O, Houkin K, et al. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res. 2004;1007(1–2):1–9
  10. Rodríguez-Sinovas A, Abdallah Y, Piper H, et al. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev. 2007;12(3–4):207–216
  11. Tse HF, Kwong YL, Chan JK, et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361(9351):47–49
  12. Hamano K, Li TS, Kobayashi T, et al. Therapeutic angiogenesis induced by local autologous bone marrow cell implantation. Ann Thorac Surg. 2002;73(4):1210–1215
  13. Schuster MD, Kocher AA, Seki T, et al. Myocardial neovascularization by bone marrow angioblasts results in cardiomyocyte regeneration. Am J Physiol Heart Circ Physiol. 2004;287(2):H525–H532
  14. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation. 2001;104(9):1046–1052
  15. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16(9):1027–1040
  16. Thiemermann C, Bowes J, Myint FP, et al. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA. 1997;94(2):679–683
  17. Sivarajah A, Collino M, Yasin M, et al. Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock. 2009;31(3):267–274
  18. Meldrum DR, Shenkar R, Sheridan BC, et al. Hemorrhage activates myocardial NFkappaB and increases TNF-alpha in the heart. J Mol Cell Cardiol. 1997;29(10):2849–2854
  19. Collino M, Aragno M, Mastrocola R, et al. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med. 2006;41(4):579–589
  20. Gorg A, Drews O, Luck C, et al. 2-DE with IPGs. Electrophoresis. 2009;30(Suppl. 1):S122–S132
  21. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics. 2004;4(12):3665–3685
  22. Stanley WC, Sabbah HN. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation. Heart Fail Rev. 2005;10(4):275–279
  23. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–1136
  24. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12(3–4):217–234
  25. Kinnaird T, Stabile E, Burnett MS, et al. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res. 2004;95(4):354–363
  26. Hausenloy DJ, Yellon DM. Cardioprotective growth factors. Cardiovasc Res. 2009;83(2):179–194
  27. Tong H, Imahashi K, Steenbergen C, et al. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase – dependent pathway is cardioprotective. Circ Res. 2002;90(4):377–379
  28. Calvert JW, Jha S, Gundewar S, et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res. 2009;105(4):365–374
  29. Masters SC, Yang H, Datta SR, et al. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol. 2001;60(6):1325–1331
  30. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231–241
  31. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1210–1221
  32. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367(9505):113–121

PII: S0021-9150(10)00590-3

doi: 10.1016/j.atherosclerosis.2010.07.045

Atherosclerosis
Volume 213, Issue 1 , Pages 67-76 , November 2010

Article Tools

* Image Usage & Resolution